ExonHit’s Drug Curbs Scopolamine’s Detrimental Effects
ExonHit Therapeutics has announced positive results of a Phase I study assessing the effects of its lead compound, EHT 0202, on scopolamine-induced brain impairments in humans.
In the study, scopolamine significantly reduced vigilance levels and cognition as measured by spectral analysis and Event Related Potentials (ERPs) respectively when administered to study subjects. The results of the spectral analysis indicate that EHT 0202 is associated with an improvement of the vigilance level at 1h15 post-dose, as shown by the significant decrease of the power in Delta and Theta bands (p
Cognitive improvement, as assessed by the analysis of P300 (an ERP wave) amplitude, was shown at an 80mg dose of EHT 0202 regardless the time post-dose (p
The Phase I, randomized, double-blind, placebo-controlled, crossover study with three treatments and the placebo being administered over four distinct periods in 12 young healthy subjects assessed the effects of single administrations of EHT 0202 (40mg, 80mg, and 120mg) on scopolamine-induced (0.6mg) cognitive impairments by using EEG recordings (spectral analysis and ERPs) at the following time points : 1h15, 2h45 4h15, 5h45 post dose.
Bruno Tocque, president of ExonHit’s management board, said: “A Phase II clinical trial is currently engaged in order to assess the safety and efficacy profile of EHT 0202 in patients suffering from Alzheimer’s disease.”